Physician profile
John E Titak
NPI 1962461319
$7,352.09
in general payments reported to CMS, 2019-2025
19 companies · $667 in 2025
The $667 reported for 2025 was more than what 84% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $770 · 2020: $472 · 2021: $908 · 2022: $1,683 · 2023: $1,066 · 2024: $1,786 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,943 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $333 · Entertainment: $243.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,942.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $333.34 |
| Entertainment | $242.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,727.87 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $1,276.69 | 2020-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $746.68 | 2022-2025 | Infuse, Xiidra, Biotrue One Day |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $708.85 | 2019-2021 | |
| Glaukos Corporation | $534.23 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $504.81 | 2022-2025 | Cequa |
| Alcon Vision LLC | $463.61 | 2019-2025 | Precision7, Simbrinza, Total30 |
| Optos, INC. | $242.83 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $187.23 | 2022 | |
| Abbvie INC. | $153.74 | 2022-2024 | |
| Maculogix, INC. | $127.16 | 2019 | |
| Harrow Eye, LLC | $125.18 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $125.00 | 2023 | Tyrvaya |
| Dompe US, INC. | $111.25 | 2024 | Oxervate |
| Lkc Technologies, INC. | $99.61 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $97.55 | 2024 | Syfovre |
| Lombart Brothers, INC. | $69.59 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $29.69 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $20.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Titak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.